COMMUNIQUÉS West-GlobeNewswire

Artios to Present at the 44th Annual J.P. Morgan Healthcare Conference
07/01/2026
CAMBRIDGE, United Kingdom and NEW YORK, January 7, 2026 – Artios Pharma Limited (“Artios”), a biopharmaceutical company committed to realizing the therapeutic power of targeting the DNA damage response (“DDR”) in cancer [...]
Inspire Medical Systems, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
07/01/2026
MINNEAPOLIS, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the fourth quarter and full year 2025 after the close of trading on Wednesday, [...]
Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next week
07/01/2026
COPENHAGEN, Denmark, January 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present at the Biotech Showcase conference [...]
Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
07/01/2026
NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that [...]
Egle Therapeutics Appoints John Celebi as Chief Executive Officer
07/01/2026
PARIS, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company pioneering precision medicines that modulate regulatory T cells (Tregs) to rebalance immune function in [...]
4DMT Provides Company Update and Anticipated Development Milestones for 2026
07/01/2026
Enrollment in 4D-150 Phase 3 wet AMD clinical trials exceeding expectations; 4FRONT-1 trial remains on track to complete enrollment in Q1 2026, with 381 patients randomized or approved to randomize as of January 6, 2026 [...]
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
07/01/2026
David Zaccardelli, Pharm.D. joins Board as Chair Rita Jain, M.D., joins Board as an Independent Director MIAMI, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage [...]
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
07/01/2026
– Common warts affects approximately 22 million patients in the United States alone, and there are no FDA approved prescription therapies for what is believed to be a multibillion-dollar market opportunity– – Verrica [...]
Bavarian Nordic Launches Planned Share Buy-Back Program
07/01/2026
COPENHAGEN, Denmark, January 7, 2026 – Bavarian Nordic A/S (OMX: BAVA) today launches the first tranche of the share buy-back program announced on December 2, 2025 , under which the Company intends to repurchase own [...]
Relation Announces Strategic Collaboration with Deerfield Management to Advance Novel Therapeutics
07/01/2026
LONDON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Relation and healthcare investment firm Deerfield Management, a current investor, today announced the establishment of a new research collaboration to advance therapeutic [...]
World-renowned Immunologist and Distinguished Scientist Joins CancerVax as Senior Scientific Advisor
07/01/2026
Dr. Mark Davis, discoverer of the first T-cell receptor genes and Stanford Professor, to advise the Company on immunological strategies for its novel cancer treatment platform Lehi Utah, Jan. 07, 2026 (GLOBE NEWSWIRE [...]
Correction: JJP Biologics Announces Positive Top-Line Phase I Trial Results of JJP-1212, its anti-CD89 antagonist
07/01/2026
Favorable safety, tolerability, pharmacokinetic and pharmacodynamic profiles validate and significantly de-risk the program Supports the feasibility of intravenous and subcutaneous dosing regimens in upcoming clinical [...]
Is MEDVi a Trusted GLP-1 Supplier for 2026? What to Know Before Choosing a Telehealth Weight Loss Platform
07/01/2026
New York City, NY, Jan. 07, 2026 (GLOBE NEWSWIRE) -- As demand for GLP-1 weight loss medications continues to rise in 2026, many consumers are actively searching for a reliable GLP-1 supplier that offers affordability, [...]
Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering
07/01/2026
BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]
Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia
07/01/2026
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 7, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel [...]
Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences
07/01/2026
Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences Halle (Saale) / Munich, Germany, January 7 , 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical [...]
JJP Biologics Announces Positive Top-Line Phase I Trial Results of JJP-1212, its anti-CD89 antagonist
07/01/2026
Favorable safety, tolerability, pharmacokinetic and pharmacodynamic profiles validate and significantly de-risk the program Supports the feasibility of intravenous and subcutaneous dosing regimens in upcoming clinical [...]
Basilea and Prokaryotics enter collaboration to develop a novel broad-spectrum antifungal for the treatment of severe invasive infections
07/01/2026
Allschwil, Switzerland, January 07, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
07/01/2026
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 7 January 2026 at 08.30 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]

Pages